Kytopen
Latest round
- Series B
Last raised
- Feb 2025
Total raised
- $41M
Investors
- 6
About Kytopen
Kytopen Corp. specializes in advanced genome engineering platforms that enhance cell therapy manufacturing efficiency.Kytopen Corp. was founded in 2017 in Cambridge, US, focusing on genome engineering solutions. The founders, Cullen Buie and Paulo Garcia, have backgrounds that contribute to the company's vision and Michael Chiu as CEO and Kevin Gutshall as CCO.Kytopen specializes in advanced genome engineering platforms designed to enhance patient access to innovative cell therapies. The company’s flagship product, Flowfect®, utilizes a unique combination of continuous fluid flow and electric fields to facilitate non-viral gene delivery, enabling efficient transfection of mRNA, DNA, and CRISPR Cas9 RNP into billions of cells within minutes. This technology is particularly beneficial during the discovery phase of drug development, addressing critical challenges in cell therapy manufacturing by allowing researchers to optimize transfection conditions for up to 96 samples simultaneously. Kytopen's offerings cater to a diverse client base including pharmaceutical companies, biotechnological firms, and academic research institutions, predominantly within North America and Europe.Kytopen generates revenue primarily through its innovative biomanufacturing solutions, especially from its Flowfect® product line designed for high-throughput transfections. The company engages in direct B2B transactions with clients, including pharmaceutical organizations and research institutions, providing essential tools for drug discovery and process optimization. Pricing models for its products accommodate varying scales of operations, though specific figures are not disclosed. By facilitating clients in overcoming gene delivery bottlenecks at the discovery stage, Kytopen fosters long-term partnerships that assist in the transition from research to commercial-scale production. Revenue streams may also include service agreements and technology access programs, reinforcing Kytopen’s role in advancing cell therapy solutions.
Who invested in Kytopen
6 investors across 4 rounds
See all investors in Kytopen
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Kytopen
Who invested in Kytopen?
Kytopen has 6 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Kytopen raised?
Kytopen has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Kytopen last raise money?
Kytopen's most recent round on record is a Series B, in Feb 2025.
What does Kytopen do?
Kytopen is a biotechnology company.
Where is Kytopen headquartered?
Kytopen is headquartered in Cambridge, US.
Which VCs invest in companies like Kytopen?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Kytopen's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Kytopen? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.